Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, Bini M, Cappelletti V, Valenti M, Baili P, de Braud FG, Folli S, Scaperrotta G, Volpi C, Vingiani A, Vernieri C, Verderio P, Miceli R, Pruneri G

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world.

Front Mol Biosci 2022; 996434. doi: 10.3389/fmolb.2022.996434

Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

PLoS Genet 2023; e1010563. doi: 10.1371/journal.pgen.1010563

Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C

Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.

Clin Breast Cancer 2023; e151-e162. doi: 10.1016/j.clbc.2022.12.008

Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, Presti D, Montelatici G, Ficchì A, Martinetti A, Arata A, Del Vecchio M, Lauria Pantano C, Formisano B, Bianchi GV, Capri G, de Braud F, Vernieri C, Fucà G

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.

Ther Adv Med Oncol 2023; 17588359231165978. doi: 10.1177/17588359231165978

Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.

NPJ Breast Cancer 2023; 27. doi: 10.1038/s41523-023-00534-1

Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini OD, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.

NPJ Breast Cancer 2023; 51. doi: 10.1038/s41523-023-00559-6

Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, Giarratano T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, Vernieri C, Curigliano G

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.

Eur J Cancer 2023; 112944. doi: 10.1016/j.ejca.2023.112944

Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.

JCO Precis Oncol 2023; e2300067. doi: 10.1200/PO.23.00067

Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchì A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F, Vernieri C

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Int J Cancer 2024; 114-123. doi: 10.1002/ijc.34701

Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, Sposetti C, Provenzano L, Azzollini J, Vingiani A, Ferraris C, Martelli G, Manoukian S, Pruneri G, de Braud F, Vernieri C

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.

Crit Rev Oncol Hematol 2023; 104109. doi: 10.1016/j.critrevonc.2023.104109

Martelli G, Barretta F, Vernieri C, Folli S, Pruneri G, Segattini S, Trapani A, Carolla C, Spatti G, Miceli R, Ferraris C

Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.

JAMA Surg 2023; 1275-1284. doi: 10.1001/jamasurg.2023.4770

Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.

Oncologist 2024; 303-310. doi: 10.1093/oncolo/oyad308

Crispo A, Augustin LSA, Luongo A, Calderaio C, Breda J, Coluccia S, Calabrese A, Marrazzo V, Giannatiempo R, Trasacco P, Palumbo E, Vitale S, Porciello G, Di Gennaro P, Caputo R, Buono G, Vernieri C, Schettini F, Grimaldi M, Nocerino F, Celentano E, Amore A, Giuliano M, De Placido P, De Angelis C, Bianco R, De Laurentiis M, La Vecchia C, Arpino G

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients.

Sci Rep 2023; 21208. doi: 10.1038/s41598-023-45439-y

Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA, Boni L, Partridge AH

Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.

JAMA 2024; 49-59. doi: 10.1001/jama.2023.25463

Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C

Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.

J Hematol Oncol 2023; 119. doi: 10.1186/s13045-023-01510-9

Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi CA, Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.

Ther Adv Med Oncol 2023; 17588359231204857. doi: 10.1177/17588359231204857

Raucci F, Vernieri C, Di Tano M, Ligorio F, Blaževitš O, Lazzeri S, Shmahala A, Fragale G, Salvadori G, Varano G, Casola S, Buono R, Visco E, de Braud F, Longo VD

Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.

Cancer Res 2024; 1133-1148. doi: 10.1158/0008-5472.CAN-23-0295

Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Cancer 2024; 2746-2762. doi: 10.1002/cncr.35323

Sorrentino L, Daveri E, Belli F, Vigorito R, Battaglia L, Sabella G, Patti F, Randon G, Pietrantonio F, Vernieri C, Scaramuzza D, Villa S, Milione M, Gronchi A, Cosimelli M, Guaglio M

Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study.

BJS Open 2024; . doi: 10.1093/bjsopen/zrae061

Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetto E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, Graff SL, Witzel I, Rodriguez Hernandez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers.

Ann Oncol 2024; 792-804. doi: 10.1016/j.annonc.2024.06.009

Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, Vernieri C, Bloomer RJ, Boschmann M, Bragazzi NL, Brandhorst S, Gabel K, Goldhamer AC, Grajower MM, Harvie M, Heilbronn L, Horne BD, Karras SN, Langhorst J, Lischka E, Madeo F, Mitchell SJ, Papagiannopoulos-Vatopaidinos IE, Papagiannopoulou M, Pijl H, Ravussin E, Ritzmann-Widderich M, Varady K, Adamidou L, Chihaoui M, de Cabo R, Hassanein M, Lessan N, Longo V, Manoogian ENC, Mattson MP, Muhlestein JB, Panda S, Papadopoulou SK, Rodopaios NE, Stange R, Michalsen A

International consensus on fasting terminology.

Cell Metab 2024; 1779-1794.e4. doi: 10.1016/j.cmet.2024.06.013

Massa D, Vernieri C, Nicolè L, Criscitiello C, Boissière-Michot F, Guiu S, Bobrie A, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci MV

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.

J Natl Cancer Inst 2024; 1914-1927. doi: 10.1093/jnci/djae178

Agostinetto E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Aguilar Y Mendez D, De Marchis L, Borea R, Puglisi F, Pistelli M, Kufel-Grabowska J, Di Rocco R, Mariamidze E, Atzori F, Kourie HR, Popovic L, de Azambuja E, Blondeaux E, Lambertini M

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

ESMO Open 2024; 103714. doi: 10.1016/j.esmoop.2024.103714

Azzollini J, Capone I, Duca M, Vingiani A, Piccolo A, Agnelli L, Tamborini E, Perrone F, Peissel B, Lorenzini D, Damian S, Vernieri C, Bianchi GV, Mantiero M, Ducceschi M, Polignano M, Niger M, Nichetti F, Proto C, Brambilla M, Colombo E, Stellato M, Conca E, Busico A, Manoukian S

Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?

Tumori 2024; 3008916241280127. doi: 10.1177/03008916241280127

Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.

Cell Metab 2025; 330-344.e7. doi: 10.1016/j.cmet.2024.11.004

Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, D'Auria G, Fedele P, Fabbri A, Vernieri C, Palleschi M, Carbognin L, Ferretti G, Di Monte E, Paris I, Pavese F, Garrone O, Franco A, De Laurentiis M, Franceschini G, Scambia G, Giannarelli D, Masetti R, Botticelli A

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.

NPJ Precis Oncol 2025; 22. doi: 10.1038/s41698-025-00801-3

Berton Giachetti PPM, Morganti S, Gandini S, Giudici F, Marra A, Nicolò E, Zattarin E, Corti C, Boldrini L, Verrazzo A, Sposetti C, Razeti MG, Carnevale Schianca A, Scafetta R, Taurelli Salimbeni B, Esposito A, Zagami P, Trapani D, Malagutti B, Caputo R, Vernieri C, Munzone E, Scagnoli S, Botticelli A, Lambertini M, Giuliano M, De Laurentiis M, Viale G, Bianchini G, Curigliano G, De Angelis C, Criscitiello C

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

JAMA Netw Open 2025; e2461067. doi: 10.1001/jamanetworkopen.2024.61067

Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status.

J Clin Oncol 2025; 1706-1719. doi: 10.1200/JCO-24-01334

Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Ann Oncol 2025; 762-774. doi: 10.1016/j.annonc.2025.03.023

De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, D'Esposito V, Poggio FB, Ruelle T, Cardinali B, Di Lauro V, Buono G, Caputo R, Buonaiuto R, Caltavituro A, Rocco P, Porciello G, De Laurentiis M, Del Mastro L, Vernieri C, Veneziani BM, Bianco R, Crispo A, De Angelis C, Arpino G, Giuliano M

Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.

Eur J Cancer 2025; 115409. doi: 10.1016/j.ejca.2025.115409

Magaton IM, Blondeaux E, Hamy AS, Linn S, Bernstein-Molho R, Peccatori FA, Ferrari A, Carrasco E, Paluch-Shimon S, Agostinetto E, Venturelli M, Luis IMV, Rodriguez-Wallberg KA, Kim HJ, Sorouri K, Renaud T, Moore HCF, Cui W, Bajpa J, Rousset-Jablonski C, De Marchis L, Yerushalmi R, Wong SM, Han S, Phillips KA, Pogoda K, Puglisi F, Chirco A, Duhoux FP, Meattini I, Villarreal-Garza C, Vernieri C, Bruzzone M, Demeestere I, Azim HA, Partridge AH, Lambertini M

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.

Eur J Cancer 2025; 115434. doi: 10.1016/j.ejca.2025.115434

Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

Lancet Oncol 2025; 759-770. doi: 10.1016/S1470-2045(25)00152-4

De Micheli V, Agnelli L, Conca E, Rabsiun Aramburu VL, Baggi A, Vingiani A, Duca M, Perrone F, Tamborini E, Piccolo A, Lorenzini D, Busico A, Capone I, Niger M, Proto C, Vernieri C, Manoukian S, Gancitano G, Ferrario M, Franzini JM, De Braud F, Pruneri G, Jommi C

Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study.

BMJ Open 2025; e099134. doi: 10.1136/bmjopen-2025-099134

Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Breast 2025; 104502. doi: 10.1016/j.breast.2025.104502

Nichetti F, Brambilla M, Duca M, Piccolo A, Miliziano D, Cavalli C, Marra F, Ambrosini P, Zanella C, Vernieri C, Lorenzini D, Colombo E, Damian S, Baili P, Proto C, Busico A, Conca E, Capone I, Manoukian S, Tamborini E, Perrone F, Niger M, Vingiani A, Agnelli L, de Braud F, Pruneri G

Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

JCO Precis Oncol 2025; e2400387. doi: 10.1200/PO-24-00387

Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Kim HJ, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Texeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA, Peccatori FA, Partridge AH, Lambertini M

Breastfeeding after breast cancer in young BRCA carriers.

J Natl Cancer Inst 2025; 2229-2239. doi: 10.1093/jnci/djaf177

Castagnoli L, Bonì F, Bigliardi M, Toneguzzo P, Corsetto PA, Galasso G, Franceschini A, Cocomazzi P, Regondi V, Capuzzoni C, Rizzo AM, Ligorio F, Vernieri C, Seneci P, Arosio D, Tagliabue E, Mastrangelo E, Milani M, Pupa SM

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.

Sci Rep 2025; 28709. doi: 10.1038/s41598-025-14639-z

Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

BMJ Open 2025; e102626. doi: 10.1136/bmjopen-2025-102626

Miglietta F, De Graaf M, Vernieri C, Piacentini F, Cacciatore M, Botticelli A, Vingiani A, Fotia G, Nicolè L, Griguolo G, Giarratano T, Massa D, Pellegrini V, Schiavi F, Porra F, Fassan M, Pruneri G, Dei Tos AP, Guarneri V, Kok M, Dieci MV

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial.

Clin Cancer Res 2025; 5306-5316. doi: 10.1158/1078-0432.CCR-25-1796

Toli MA, Liu X, Massa D, Lando S, Boman C, Tsiknakis N, Tranchell C, Papakonstantinou A, Fotia G, Vernieri C, Guarneri V, Bergh J, Dieci MV, Bergman LE, Matikas A, Foukakis T

Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.

Lancet Reg Health Eur 2025; 101432. doi: 10.1016/j.lanepe.2025.101432

Buonaiuto R, Fordellone M, Caltavituro A, Cataldo ML, Criscitiello C, Dieci MV, Lambertini M, Botticelli A, Giuliano M, Giordano A, Mangiacotti F, Grieco A, Longobardi A, Caputo R, Pagliuca M, Vernieri C, Malorni L, Gerratana L, Arpino G, Chiodini P, De Laurentiis M, De Angelis C

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

EClinicalMedicine 2025; 103535. doi: 10.1016/j.eclinm.2025.103535

Martelli G, Barretta F, Muzi C, Listorti C, Pilotta F, Maugeri I, Osio C, Bonfili D, Vernieri C, Bianchi G, Pruneri G, Folli S, Scaperrotta G, Baili P, Miceli R, Ferraris C

Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study.

Ann Surg Oncol 2026; 2255-2266. doi: 10.1245/s10434-025-18673-z

Pisegna S, Scagnoli S, Gentile G, Chiavassa A, Caputo R, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Orlandi A, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri MA, Rossi L, Fiscon G, Marchetti P, Fabi A, Botticelli A

Clinical characteristics and drug-drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study.

Oncologist 2026; . doi: 10.1093/oncolo/oyaf402

Mazzoli G, Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Fotia G, De Monte M, Ligorio F, Jacobs F, Armani G, Zurlo C, Menichetti A, Griguolo G, Faso V, Schianca AC, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.

Breast 2026; 104692. doi: 10.1016/j.breast.2026.104692

Dauccia C, Bruzzone M, Arecco L, Blondeaux E, Sirico M, Gerosa R, Franzoi MA, Brandão M, Perrone L, Pedrazzoli P, Desmedt C, Di Cosimo S, Vernieri C, Collet L, Lambertini M, de Azambuja E, Agostinetto E

Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis.

Breast 2026; 104710. doi: 10.1016/j.breast.2026.104710

Scafetta R, Troiano R, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Donato M, Foderaro S, Venuti F, Vilardi FA, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Garrone O, Domati F, Piombino C, Lisa FSD, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Livi L, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, Giorgi U, Vici P, Toss A, Ruatta F, Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Chirco A, D'Alessandro S, Vincenzi B, Tonini G, Santini D, Pantano F

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Eur J Cancer 2026; 116703. doi: 10.1016/j.ejca.2026.116703

Becherini C, Blondeaux E, Delucchi V, Visani L, Kim HJ, Coussy F, Bernstein-Molho R, Di Meglio A, Hilbers FS, Pogoda K, Kwong A, Agostinetto E, Baten A, Bajpai J, Balmana J, Moore HCF, Partridge AH, Rousset-Jablonski C, Phillips KA, Toss A, Renaud T, Ferrari A, Peccatori FA, Sanchez L, Paluch-Shimon S, Cui W, Wong SM, Ryu JM, Fruscio R, Lee MK, Vernieri C, Matikas A, Couch FJ, De Marchis L, Dieci MV, Aguilar-Y-Mendez D, Hwang SE, Rozenblit M, Can Güven D, Mrinakova B, Harbeck N, Sanchez-Bayona R, Boni L, Lambertini M, Meattini I

Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.

Radiother Oncol 2026; 111523. doi: 10.1016/j.radonc.2026.111523

Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Venuti F, Vilardi FA, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, La Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Chirco A, D'Alessandro S, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Oncologist 2026; . doi: 10.1093/oncolo/oyag146

%PLACEHOLDER%